Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

105.08 +0.73 (+0.70%)
Streaming Delayed Price Updated: 3:21 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,788,740
Open 104.63
Bid (Size) 105.07 (1)
Ask (Size) 105.08 (3)
Prev. Close 104.35
Today's Range 103.88 - 105.26
52wk Range 89.67 - 115.83
Shares Outstanding 1,750,942,289
Dividend Yield 1.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga

Performance

YTD
-4.11%
-4.11%
1 Month
+10.61%
+10.61%
3 Month
+4.16%
+4.16%
6 Month
+2.40%
+2.40%
1 Year
-0.31%
-0.31%

More News

Read More
Spotlight on Abbott Laboratories: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Jim Cramer: Buy This Financial Stock, 'I Think They're High Quality'
Via Benzinga
Medtronic: oversold, overextended high yield reversal in play
Via MarketBeat
Exposures COVID-19
1 Stock Down 15% This Year to Buy and Hold Forever
Via The Motley Fool
2 No-Brainer Dividend Stocks to Buy This Week
Via The Motley Fool
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Via Benzinga
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
Via The Motley Fool
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
Via FinancialNewsMedia
Exposures COVID-19
3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing
Via The Motley Fool
Novo Nordisk, Eli Lilly Skid — But These Weight-Loss Results Are 'Hard To Ignore'
Via Investor's Business Daily
2 No-Brainer Stocks to Buy for Forever Dividend Growth
Via The Motley Fool
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Dividend Kings to Buy for Royal Returns
Via InvestorPlace
Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Dividend Stocks That Are Investor Safe Havens
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
SLB, Abbott And 2 Other Stocks Insiders Are Selling
Via Benzinga
MedTech Giant DexCom Spotlight Is On G7 US Launch, Analyst Forecasts 22% Revenue Gain In 2024
Via Benzinga
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
Via The Motley Fool
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
Via MarketBeat
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.